BYOM-1022: once-monthly injection for anxiety treatment
BYOM-1022 is a once-monthly subcutaneous injection targeting GDF-15 to treat anxiety without CNS side effects. It rapidly reverses corticosterone increase, offering a fast-acting, non-sedative solution for anxiety management.
Overview
BYOM-1022 is a novel therapeutic approach to anxiety management, leveraging the role of GDF-15, a biomarker associated with chronic diseases and stress responses. This once-monthly subcutaneous injection works by neutralizing serum GDF-15, thereby preventing its effects on the HPA axis and reducing corticosterone levels. This precision medicine approach offers a unique advantage by targeting anxiety without causing CNS side effects, providing a safe and effective treatment option.
Technical specifications
- Target Mechanism: Neutralizes serum GDF-15, preventing its interaction with GFRAL receptors in the brainstem, which are responsible for increasing corticosterone levels.
- Administration: Once-monthly subcutaneous injection.
- Efficacy: Demonstrated ability to reverse GDF-15-induced corticosterone increase, leading to anxiolytic effects.
- Safety Profile: Fast-acting without causing sedation, making it a suitable option for those seeking non-drowsy anxiety relief.
Technology readiness level
BYOM-1022 is currently at Technology Readiness Level 5, having shown efficacy in preclinical models and demonstrating potential for further validation in clinical settings. Future studies aim to establish proof of mechanism in patients with severe anxiety, particularly those with elevated serum GDF-15 and cortisol levels.
About BYOMass Inc.
BYOMass is a preclinical pharmaceutical company that develops biologic and small molecule drugs targeting specific members of the TGF-β superfamily. The company focuses on modulating these pathways to address orphan and common diseases, with potential therapeutic applications in oncology, inflammatory, immune, fibrotic, and metabolic conditions. Founded by V. Margaret Jackson, the company employs a pathway-driven, scientific approach to drug discovery, combining the expertise of an experienced pharmaceutical leadership team with the agile operational structure of a startup to advance novel candidates through preclinical stages.
This work is critical for patients suffering from conditions with high unmet medical needs where traditional therapies have been ineffective. By employing systems pharmacology modeling and mechanistic research, BYOMass aims to de-risk its pipeline and optimize the development of its lead candidates. The company collaborates with organizations such as Applied BioMath to refine its therapeutic platforms and has engaged industry experts to its board of directors to support its mission of bringing transformative treatments from early-stage research toward clinical development.
delivered to your inbox.